rTMS for Depression

"At the present moment, 7 trials concerning [11C]UCB-J radiotracer are being held in 11 cities and 3 countries. This medication was originally tested back in 2018 by RDD Pharma Ltd., who recruited 40 patient for a Phase 1 trial. Since then, an additional 53 studies have been conducted on this tracer drug."

"This clinical trial is no longer accepting applicants. It was originally published on February 1, 2022 and the most recent edits were made on September 20, 2021. For those searching for another medical study to partake in, there are 826 trials currently enrolling melancholic patients and 7 studies recruiting participants for [11C]UCB-J radiotracer testing."

"Presently, 7 clinical trials of [11C]UCB-J radiotracer are ongoing. None have reached Phase 3 yet. Most experiments occur in Raleigh, North carolina; however, the therapy is being tested at 12 different sites around the US."

"The study is accepting patients between 18 and 70, with 106 trials for minors and 600 for those older than 65."

"The [11C]UCB-J radiotracer is effective in treating anesthesia, conduction, persistent facial erythema, and rhinorrhoea."

"The safety of [11C]UCB-J radiotracer is given a score of 1 by our team at Power, as this falls under Phase 1 trials and thus has limited data confirming its efficacy and security."

"This trial is accepting 10 individuals aged 18-70 suffering from melancholia. Moreover, successful applicants must be on a stable medication plan for two weeks prior to the start of testing, have secure living arrangements and medical health, and agree to receive repetitive Transcranial magnetic stimulation (rTMS) at VA Palo Alto Health Care System."

"This trial, which was first advertised on February 1st 2022, is no longer actively recruiting. As seen in the clinicaltrials.gov database, this medical research project's last update was on September 20th 2021; yet 833 other trials are currently looking for participants."